|
|
 | | | |
- close
- close
- close
- close
VRUS » Topics » Delays in clinical trials could result in increased costs to us and delay our ability to obtain regulatory approval and commercialize our product candidates.These excerpts taken from the VRUS 10-K filed Dec 11, 2008. Delays in clinical trials could result in increased costs to us and delay our ability to obtain regulatory approval and commercialize our product candidates. Significant delays in clinical trials could materially affect our product development costs and delay regulatory approval of our product candidates. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including:
Delays in clinical trials could result in increased costs to us and delay our ability to obtain regulatory approval and Significant delays in clinical trials could materially affect our product development costs
We have experienced, and expect to experience in the future, delays in patient/subject enrollment in our clinical trials for a variety of
45 Table of Contents
competition reduces the number and types of patients/subjects available to us, because some patients/subjects who might have opted to enroll in our trials opt to enroll in a trial being conducted by one of our competitors. We conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which reduces the number of patients/subjects who are available for our clinical trials in such clinical trial site. Delays in patient enrollment in the future as a result of these and other factors may result in increased costs or may affect the timing or outcome of our clinical trials, which could prevent us from completing these trials and adversely affect our ability to advance the development of our product candidates. For example, in our Phase 2 study of Racivir, we anticipated that enrollment would take less than one year to approval or limit their use if approved. We must demonstrate the safety of our product candidates to obtain regulatory approval. This excerpt taken from the VRUS 10-K filed Dec 31, 2007. Delays in clinical trials could result in increased costs to us and delay our ability to obtain regulatory approval and commercialize our product candidates. Significant delays in clinical trials could materially affect our product development costs and delay regulatory approval of our product candidates. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including:
This excerpt taken from the VRUS 10-Q filed Aug 9, 2007. Delays in clinical trials could result in increased costs to us and delay our ability to obtain regulatory approval and commercialize our product candidates. Significant delays in clinical trials could materially affect our product development costs and delay regulatory approval of our product candidates. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including:
28
Table of Contents
This excerpt taken from the VRUS 10-Q filed Jun 11, 2007. Delays in clinical trials could result in increased costs to us and delay our ability to obtain regulatory approval and commercialize our product candidates. Significant delays in clinical trials could materially affect our product development costs and delay regulatory approval of our product candidates. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including:
| EXCERPTS ON THIS PAGE:
|
| |||||||
